Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial

By December 21, 2020 No Comments

“Lesser or stable disability over two years was evident in most progressive multiple sclerosis (MS) patients given a stem cell treatment in a small Phase 1 clinical trial, supporting a larger study now underway, researchers report.

These results suggest that a treatment using mesenchymal stem cell-derived neural progenitors (MSC-NPs) can safely and effectively ease inflammation in progressive MS.

But for a subset of patients, particularly those with more advanced disease and greater disability, this treatment did not sufficiently counter a continued inflammatory response in the brain”

Click Here for Report

error: Content is Property of SMSbiotech